key: cord-0758959-ntwloz7o authors: Olaleye, Omonike A.; Kaur, Manvir; Onyenaka, Collins C. title: Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein’s Receptor Binding Domain and Recombinant Human ACE2 date: 2020-09-14 journal: bioRxiv DOI: 10.1101/2020.09.13.295691 sha: e932f7a5d8c7f4b8ab33a69c2a6b89f1da4f8275 doc_id: 758959 cord_uid: ntwloz7o Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), enters the host cells through two main pathways, both involving key interactions between viral envelope-anchored spike glycoprotein of the novel coronavirus and the host receptor, angiotensin-converting enzyme 2 (ACE2). To date, SARS-CoV-2 has infected up to 26 million people worldwide; yet, there is no clinically approved drug or vaccine available. Therefore, a rapid and coordinated effort to re-purpose clinically approved drugs that prevent or disrupt these critical entry pathways of SARS-CoV-2 spike glycoprotein interaction with human ACE2, could potentially accelerate the identification and clinical advancement of prophylactic and/or treatment options against COVID-19, thus providing possible countermeasures against viral entry, pathogenesis and survival. Herein, we discovered that Ambroxol hydrochloride (AMB), and its progenitor, Bromhexine hydrochloride (BHH), both clinically approved drugs are potent effective modulators of the key interaction between the receptor binding domain (RBD) of SARS-CoV-2 spike protein and human ACE2. We also found that both compounds inhibited SARS-CoV-2 infection-induced cytopathic effect at micromolar concentrations. Therefore, in addition to the known TMPRSS2 activity of BHH; we report for the first time that the BHH and AMB pharmacophore has the capacity to target and modulate yet another key protein-protein interaction essential for the two known SARS-CoV-2 entry pathways into host cells. Altogether, the potent efficacy, excellent safety and pharmacologic profile of both drugs along with their affordability and availability, makes them promising candidates for drug repurposing as possible prophylactic and/or treatment options against SARS-CoV-2 infection. with shaking at 180 rpm. Thereafter, the solution was discarded and the plate was washed 213 consecutively four times with 300 µL 1X wash buffer, followed by the addition of the detection 214 antibody (anti-ACE2 goat antibody). The reaction was allowed to go on for 1 hr at room 215 temperature (22°C) with shaking at 180rpm. Then, the solution was discarded and the wash 216 step was repeated as described above. Next, the HRP-conjugated anti-goat IgG was added to 217 each well, and the reaction plate was further incubated for 1 hr at room temperature (22°C) with 218 shaking at 180rpm. Again, the solution was discarded and the wash step was repeated as 219 described above. Then, 100µL of 3,3',5,5'-tetramethylbenzidine (TMB) one-step substrate was 220 added to each well, and reaction mixtures were incubated in the dark at room temperature The interaction of human ACE2 and the receptor binding domain (RBD) of the SARS-CoV-2 S 238 protein has been reported as a critical step in viral infection for both the endocytosis and non-239 endocytosis pathways of viral entry into host cells [10] [11] [12] [13] [14] [15] 43 . We evaluated the effect of AMB and 240 its progenitor, BHH on the binding affinity of rhACE2 and RBD of SARS-CoV-2 S protein at 241 concentrations ranging from 100 µM to 100 nM, using an adapted in vitro enzyme-linked 242 immunoabsorbent assay (ELISA) 42 . We observed a unique dose-response curve for both 243 compounds (using the special bell shape curve model). AMB displayed the highest inhibition of 244 S (RBD)-rhACE2 protein interaction at lower micromolar concentrations (ranging from 100nM to 245 10µM); compared to higher concentrations of AMB from 50 µM ( Figure 1B ). Interestingly, we 246 found that BHH inhibited the binding of SARS-CoV-2's S (RBD) protein to rhACE2 receptor at 247 lower concentrations ranging from 100 nM to 10 µM; but enhanced the interaction at higher 248 concentrations of BHH from 50 µM ( Figure 1A ). Hence, the bell shaped model generated two IC 50 values (IC 50_1 and IC 50_2 ) as shown in Table 4 . Unlike BHH, we did not observe a stimulation 250 or enhancement of binding of SARS-CoV-2's Spike (RBD) protein to rhACE2 receptor for its 251 metabolite -AMB, at the concentrations we tested. However, using the bell curve model, the 252 graphpad software generated a second IC 50_2 at 232 µM for AMB, greater than the highest 253 concentration tested (100 µM). Moreover, the unconventional dose response curve observed in 254 this protein interaction assay, could be intrinsic to the mode of inhibition or an indicator of 255 additional binding site(s) and/or target(s), for the BHH and AMB, such as other sites on rhACE2 256 or the Spike (RBD) protein. To our knowledge, these finding is the first report to reveal that AMB 257 inhibits and interferes with the binding between rhACE2 receptor and SARS-CoV-2 S (RBD) 258 glycoprotein in vitro; while BHH inhibits this critical interaction at lower concentrations and 259 enhances at higher concentrations (Table 4 ). These results suggest that AMB might be a The rapid identification and repurposing of clinically approved drugs with antiviral activity against Using a Cell Titer-Glo Luminescent Cell Viability Assay 41 , we determined the cytotoxicity of AMB 291 and BHH. We also assessed the cytotoxic effects of the reference compounds in Vero E6 cells 292 and observed that, the 50% cytotoxic concentration (CC 50 ) of AMB and BHH were greater than 293 30 µM. In comparison to the other reference compounds tested, AMB and BHH displayed 294 slightly higher percent maximum and minimum viability at the concentrations tested (Table 3) . Between the two compounds, we observed a higher percent minimum viability for AMB 296 (113.95%), compared to its progenitor, BHH (103.87%) at 30 µM (Table 3) The emergence of novel SARS-CoV-2 strains has imposed an urgent call to accelerate the 305 repurposing and advancement of existing clinically safe and approved drugs as effective 306 prophylactic and/or therapeutic agents for combating the COVID-19 pandemic. The crystal 307 structure of full length human ACE2 revealed that the RBD on SARS-CoV-2 S1 binds directly to 308 the metallopeptidase domain (MPD) of ACE2 receptor [10] [11] [12] [13] . In this study, we explored the 309 possibility of a clinically safe and approved drug, AMB and its progenitor, BHH as potential Although, AMB was found to be the most potent against rhACE2-RBD interaction in the 347 biochemical assay compared to BHH; however, in the cellular CPE assay, AMB had a higher IC 50 348 than BHH for antiviral activity. Additionally, we observed that the IC 50 values of the compounds in 349 the cellular CPE assay were much higher than the IC 50s in the rhACE2-Spike(RBD) protein 350 interaction assay, although the special bell curve model produced two IC 50s due to the mode of Altogether, our findings provide a novel protein-protein interaction target and strong supporting 365 evidence that may explain the mechanism of action for the AMB and BHH pharmacophore ( Figure 366 2). In addition, we conducted a comparative analysis of the dose-response curves of antiviral 368 activity and cytotoxicity of AMB and BHH with five other known inhibitors of SARS-CoV-2 in vitro, hand, when we assessed the cytotoxicity of AMB and BHH in Vero E6 cells, we observed that 373 both compounds displayed higher percent maximum and minimum viability at the concentrations 374 tested (Table 3) compared to the other reference compounds. Moreover, AMB had a slightly 375 higher percent minimum viability compared to BHH, consistent with other reported safety studies 376 for both compounds, that demonstrate that AMB has superior safety profile than BHH 51 . Thus, 377 considering that AMB is safe and clinically approved, our findings that AMB significantly inhibited In addition to their impact on lung physiology and function with regards to mucociliary clearance, However in a recent study, unlike Camostat, another known TMPRSS2 inhibitor; AMB and BHH mode of SARS-CoV-2 inhibition. The clinical advancement of the AMB pharmacophore could potentially accelerate their 408 consideration for repurposing as potential antiviral agents against COVID19, in non-human World Health Organization. Director-General's opening remarks at the media briefing on 475 COVID-19 Coronavirus resource 479 center: COVID-19 dashboard by the Center for Systems Science and Engineering The four 486 horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection Potential Antiviral Drugs Under Evaluation for the 489 Treatment of COVID-19 COVID-19): A Review No Benefit for Lopinavir-Ritonavir in Severe COVID-19 Current updates on the European and WHO 12 Structural and Functional Basis of SARS-CoV-2 Entry 508 by Using Human ACE2 Structure, Function, 510 and Antigenicity of the SARS-CoV-2 Spike Glycoprotein SARS-CoV-2 Cell Entry Depends on 513 ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor CoV-2 infection of human small intestinal enterocytes ACE2 X-Ray Structures Reveal a Large Hinge-519 bending Motion Important for Inhibitor Binding and Catalysis Structural biology: Structure of SARS coronavirus 522 spike receptor-binding domain complexed with receptor Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural 525 Ambroxol in the 21st century: Pharmacological and clinical 24 A reappraisal of the mucoactive activity and clinical 35 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Hydroxychloroquine, a less toxic derivative of chloroquine, is 610 effective in inhibiting SARS-CoV-2 infection in vitro Drug Repurposing Screen for Compounds Inhibiting 613 the Cytopathic Effect of SARS-CoV-2. bioRxiv CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in the requirements for 617 receptor expression and proteolytic activation and are not inhibited by Bromhexine. 618 bioRxiv Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant 622 In vitro screening of a FDA approved chemical library 624 reveals potential inhibitors of SARS-CoV-2 replication Ambroxol: A CNS Drug? Molecular dynamics reveals complex 629 compensatory effects of ionic strength on the SARS-CoV-2 Spike/hACE-2 interaction. 630 bioRxiv The authors declare no competing interests.